Feist-Weiller Publishes Its Biannual Report
Feist-Weiller Cancer Center has a Cancer Committee which is a multidisciplinary team that meets each month. It is responsible for monitoring, assessing, and identifying changes that are needed to maintain compliance with the American College of Surgeons Standards for accreditation. The information provided in this report reflects our institution’s ongoing commitment to quality cancer care. Dr. Robin Lacour has chaired the committee, and Dr. Vita Mehta served a liaison physician.
The Cancer Liaison Physician for the Feist-Weiller Cancer Center evaluates, interprets and reports on our program’s performance using data from the National Cancer database in order to identify areas where we can improve the quality of care. Over the past year, discussions have included FWCC/University Health breast, colon, head and neck, lung and ovarian cancer statistics. A common theme noted among all of these cancer types is that our cancer center remains true to its mission by demonstrating excellence in care for the indigent population of Louisiana.
When comparing our statistics with national data for publicly or uninsured patients and those who have to travel far distances to receive cancer care, the FWCC stands out as a cancer center where patients’ outcomes are equivocal regardless of their issues with access to care. This trend does not hold true nationally where patients with challenges in accessing care exhibit significantly worse survival, even when controlled for other factors.
Additionally, we have identified areas of improvement that will further strengthen our commitment to cancer care and has led to us becoming nationally recognized as a center of excellence. Through data obtained from our breast cancer statistics, we have made improvements in our breast cancer conservation therapy, and will be applying to become a nationally accredited breast cancer program through the American College of Surgeons.
To read the full report, click here.
Society Of Basic Urologic Research Names
New Vice President
The Society for Basic Urologic Research (SBUR) has announced that Hari K. Koul , M.Sc., Ph.D. has been elected as SBUR Vice President to serve a one year term until May 2016, at which time Dr. Koul will ascend to the office of President.
Koul is the Professor and Chairman of the Department of Biochemistry and Molecular Biology, Carroll W. Feist Endowed Chair in cancer, LSU School of Medicine -Shreveport. He also serves as Director of Basic and Translational Research at Feist-Weiller Cancer Center, LSU Health Sciences Center - Shreveport.
Koul pioneered the field of oxalate nephrotoxicity and these NIH-RO1 funded studies focus on evaluating the molecular signaling pathways associated with oxalate nephrotoxicity. In addition Dr. Koul identified tumor metastasis function of Sam Pointed Domain Ets Factor (SPDEF) and current studies in his laboratory are focused at identifying regulatory mechanisms by which SPDEF modulates expression of downstream target genes. Koul’s work includes research in prostate, bladder, and kidney cancer.